New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2013
18:48 EDTBX, GSKBlackstone, LIon Capital to bid for GSK's soft drinks, Sky News says
Blackstone (BX) and Lion Capital have teamed up to submit a formal bid for the two soft drinks Lucozade and Ribena, which have been put up for sale by drugmaker GlaxoSmithKline (GSK), says Sky News. Reference Link
News For BX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
18:37 EDTGSKViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
July 1, 2015
12:19 EDTBXBlackstone, JPMorgan among giants interested in Worldpay, Sky News says
Subscribe for More Information
June 30, 2015
16:05 EDTBXBlackstone completes acquisition of Tiptree Financial subsidiary
Subscribe for More Information
13:59 EDTBXBlackstone intends to inject $84M into Jack Wolfskin, Bloomberg reports
Blackstone plans to inject $84M into Jack Wolfskin to alter the terms on its senior loans, Bloomberg reports, citing two people familiar with the matter. Reference Link
08:58 EDTBXWendel to acquire AlliedBarton Security Services for roughly $1.67B
Subscribe for More Information
05:37 EDTBXBlackstone to sell AlliedBarton to Wendel SE for $1.67B
Blackstone announced that private equity funds it manages have agreed to sell AlliedBarton to Wendel SE for approximately $1.67B. The transaction is expected to close later this year, and is subject to customary regulatory approvals.
05:37 EDTBXBlackstone to sell AlliedBarton to Wendel SE for $1.67B
Subscribe for More Information
June 29, 2015
06:07 EDTBXBMW, Macquarie expected to bid for ANZ Banking unit, Reuters reports
According to a source familiar of the situation, BMW and Macquarie Group are among the companies expected to make a bid for Australia and New Zealand Banking Group's car and equipment loan book, Reuters reports. Additionally, buyout firms Carlyle (CG), Blackstone (BX) and TPG have requested information memorandums for the sale. The unit could fetch more than the $6.35B book value of the loans, the source says. Reference Link
June 26, 2015
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
June 23, 2015
10:19 EDTBXReno shoe chain hires bankers to explore sale, Reuters reports
Subscribe for More Information
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use